Neurotx
1 known investors
NeuroTx is an AI neurotechnology platform that decodes multi-modal bio-signals (EEG, ECG, PPG, EMG, HRV, actigraphy) using Neural Decoding AI to power personalized neuro-intervention solutions including electroceuticals, VNS, and BCI. Its applications span sleep, cognition, metabolic health, neurorehabilitation, and communication.
Also known as NeuroTx
Investors · 1
Company profile
researched Aug 2026NeuroTx is a South Korean neurotechnology company that analyzes multi-modal bio-signals — EEG, ECG, PPG, EMG, HRV and actigraphy — with what it calls Neural Decoding AI, and translates the resulting neural state estimates into personalized neuro-intervention. Its stated product scope covers electroceuticals, closed-loop vagus nerve stimulation (VNS), brain-computer interface (BCI) platforms for mobility, rehabilitation and communication, and digital neuro-intervention software. Application areas described by the company include sleep optimization, brain wellness, cognitive support, neurorehabilitation and metabolic health.
The company's lead product is WillSleep, an AI sleep healthcare platform that pairs real-time multimodal biometric monitoring (including PPG and ECG) with non-invasive transcutaneous vagus nerve stimulation (tVNS). Operating in a closed loop, the system calibrates micro-stimulation to the user's immediate physiological state with the aim of restoring autonomic nervous system balance and improving sleep architecture, positioned as an alternative to pharmaceutical sleep aids. NeuroTx is also developing an expanded electroceutical portfolio aimed at mild cognitive impairment, Alzheimer's dementia, obesity and early-stage Parkinson's disease, which it has said it intends to unveil by 2027 for the AgeTech market.
NeuroTx is led by CEO Dong-Joo Kim, a professor in the Department of Brain and Cognitive Engineering at Korea University, where NeuroTx is identified as the technology holding company associated with his Brain Lab. Preqin lists the company as established in 2015 in Seoul, South Korea, classified under Healthcare IT and at an early stage.
Founding story
NeuroTx is identified as the technology holding company of the Brain Lab at Korea University led by Prof. Dong-Joo Kim, who serves as the company's CEO and holds a PhD in engineering from the University of Cambridge with prior research posts at Addenbrooke's Hospital and the University of Toronto.
Business model
NeuroTx develops and manufactures neurostimulation hardware combined with AI software platforms, and pursues both direct-to-consumer wellness channels and enterprise institutional healthcare systems. It works with academic medical centers on clinical validation, partners with regional distributors for market entry (for example Haslux in Japan), and targets clinical research organizations, healthcare networks and investors for collaboration and distribution.
Sales of neurostimulation devices, complemented by an intended bridge between direct-to-consumer wellness offerings and enterprise institutional healthcare sales; Preqin additionally describes subscription-based access to accompanying digital platforms.
Traction
The company reports 71+ SCI publications, 66+ patents, four university hospital networks and 93% sleep stage classification accuracy. In collaborative clinical trials with Korea University Anam Hospital, Seoul National University Hospital and the Catholic University of Korea, WillSleep demonstrated an 82% efficacy rate in improving sleep quality among participants. The underlying technology was named a CES 2026 Innovation Award Honoree in the Digital Health category. Preqin reports one completed funding deal with Kakao Ventures as an investor.
Latest developments
NeuroTx is scheduled to make its international debut at the BIO International Convention 2026 (San Diego, June 22-25, 2026), showcasing WillSleep. Its regulatory affairs teams are running parallel compliance tracks for European CE (MDR) and U.S. FCC certifications, and production lines have been set up to ISO 13485 and GMP requirements. A Japanese commercial launch is planned for the second half of 2026, and the company has stated it is seeking to close its next corporate funding rounds.
▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies
Market position
An early-stage Korean digital health and bioelectronic medicine company positioned in non-invasive, AI-driven neurostimulation for chronic neurological conditions, presenting its patent portfolio and neural-decoding architecture as a technical barrier to entry.
Combines real-time multimodal biometric decoding with closed-loop, individually calibrated non-invasive vagus nerve stimulation rather than fixed-parameter stimulation, positioned against pharmaceutical sleep aids on dependence and systemic side-effect risk, and supported by a patent portfolio and hospital-based clinical validation.
Technology
A neural-decoding AI architecture performs real-time analysis of multi-modal bio-signals (EEG, ECG, PPG, EMG, HRV, actigraphy) and personalizes intervention. This feeds a closed-loop framework that delivers adaptive stimulation and feedback guidance, notably non-invasive transcutaneous vagus nerve stimulation calibrated to the user's immediate physiological state, plus a BCI platform for mobility, rehabilitation and communication. The company cites a portfolio of over 50 patents behind the WillSleep platform (66+ patents overall on its website) and 93% sleep stage classification accuracy.
Go-to-market
International visibility through trade events, including a debut at the BIO International Convention 2026 in San Diego alongside 76 other Korean exhibitors, with live technical demonstrations and closed-loop demo rooms intended to secure research collaborations, hardware distribution deals and funding. Regionally, the company uses local retail and clinical partnerships (Haslux in Japan) and is pursuing regulatory clearances for European and U.S. entry.
Consumers seeking sleep, cognitive and recovery support; healthcare providers, hospitals and clinical research organizations; and, in later phases, patients with mild cognitive impairment, Alzheimer's dementia, obesity and early-stage Parkinson's disease. The company emphasizes hyper-aging populations in East Asia and Western Europe.
Geography
Headquartered in Seoul, South Korea. A retail and clinical partnership is in place in Japan, with commercial launch there scheduled for the second half of 2026, and targeted expansion into France, Germany and the Netherlands; the company is also targeting counterparties across East Asia and Western Europe.
History
Preqin records NeuroTx as established in 2015 in Seoul, South Korea, in the Healthcare IT sector, at an early stage of development with one completed funding deal and Kakao Ventures among its investors.
Risks & controversies
Key European and U.S. market access depends on pending CE (MDR) and FCC certifications that had not been secured as of the reporting. The company has stated it is still seeking to close its next funding rounds, and its expansion plans for metabolic and degenerative disease indications, plus the Japanese commercial launch, remain forward-looking.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 5
launches, deals, and filingsNeuroTx exhibits at the BIO International Convention 2026 in San Diego (June 22-25, 2026), showcasing its WillSleep AI closed-loop tVNS sleep platform and seeking research collaborations, distribution and investors.
NeuroTx's underlying closed-loop neural decoding technology was named a CES 2026 Innovation Award Honoree in the Digital Health category.
NeuroTx plans a formal commercial launch in Japan in the second half of 2026, followed by targeted expansion into France, Germany and the Netherlands; regulatory teams are pursuing CE (MDR) and U.S. FCC certifications.
NeuroTx formed a retail and clinical partnership with Haslux to develop localized commercial models and integrate its devices into Japanese medical networks.
NeuroTx states its production lines comply with ISO 13485 medical device quality management standards and Good Manufacturing Practice requirements.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 8
primary sources listed
- Neurotxneurotx.kr · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Neurotx do?
- Korean neurotechnology company using AI bio-signal decoding to drive closed-loop vagus nerve stimulation and BCI interventions.
- Who are Neurotx's investors?
- Neurotx's investors include Kakao Ventures.